Duchenne Muscular Dystrophy Clinical Pipeline Accelerates: Over 75 Companies Advancing Next-Generation Therapies | DelveInsight

AI Briefing

• – Over 75 companies are advancing next-generation therapies for Duchenne Muscular Dystrophy.
• – Duchenne Muscular Dystrophy is being targeted by multiple companies with various approaches including gene therapies, antisense oligonucleotides and gene editing technologies.
• – Santhera Pharmaceuticals, Sarepta Therapeutics, and others are leading the charge in developing treatments for the disease.